Cargando…

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

BACKGROUND: Screening men for prostate cancer using prostate-specific antigen (PSA) testing remains controversial. We aimed to estimate the likely budgetary impact on secondary care in England and Wales to inform screening decision makers. METHODS: The Cluster randomised triAl of PSA testing for Pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thorn, Joanna C., Turner, Emma L., Walsh, Eleanor I., Donovan, Jenny L., Neal, David E., Hamdy, Freddie C., Martin, Richard M., Noble, Sian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257301/ https://www.ncbi.nlm.nih.gov/pubmed/37296430 http://dx.doi.org/10.1186/s12913-023-09503-7

Ejemplares similares

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C, et al.
Publicado: (2016)

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Turner, E L, et al.
Publicado: (2014)

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
por: Williams, Naomi J, et al.
Publicado: (2015)

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)
por: Merriel, Samuel William David, et al.
Publicado: (2017)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Survey of the rate of PSA testing in general practice
por: Melia, J, et al.
Publicado: (2001)

A New Interpretation of the Standard PSA-Test
por: Esteban, Ernesto P, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

Routine PSA Testing: An Analysis of the Controversy Concerning Its Use
por: Hussain, Namath S.
Publicado: (2005)

Is serum PSA a predictor of male hypogonadism? Testing the hypothesis
por: Amadi, Collins, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

Treat-to-target in PsA: methods and necessity
por: Dures, Emma, et al.
Publicado: (2020)

Galectin-3: a possible complementary marker to the PSA blood test
por: Balan, Vitaly, et al.
Publicado: (2013)

Yinglu Guo: PSA screening test requires wider application in China
por: Song, Xiaoping
Publicado: (2012)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

PsaF Is a Membrane-Localized pH Sensor That Regulates psaA Expression in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2021)

Doctors’ approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study
por: Pickles, Kristen, et al.
Publicado: (2015)

Rheological and Mechanical Properties of an Acrylic PSA
por: Simões, Beatriz D., et al.
Publicado: (2023)

PSA 1972 : proceedings of the 1972 biennial meeting philosophy of science association
Publicado: (1974)

Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements
por: McJimpsey, Erica L.
Publicado: (2016)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
por: Pashayan, N, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_02a1o6o2a3o63u5c87stpirghf